Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Horizon Pharma Plc - Key Facts

Horizon Pharma Plc - Key Employees

Horizon Pharma Plc - Key Employee Biographies

Horizon Pharma Plc - Major Products and Services

Horizon Pharma Plc - History

Horizon Pharma Plc - Company Statement

Horizon Pharma Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Horizon Pharma Plc - Business Description

Business Segment: Orphan and Rheumatology

Overview

Performance

Business Segment: Primary Care

Overview

Performance

Geographical Segment: Rest of World

Performance

Geographical Segment: United States

Performance

Horizon Pharma Plc - Corporate Strategy

Horizon Pharma Plc - SWOT Analysis

SWOT Analysis - Overview

Horizon Pharma Plc - Strengths

Horizon Pharma Plc - Weaknesses

Horizon Pharma Plc - Opportunities

Horizon Pharma Plc - Threats

Horizon Pharma Plc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Horizon Pharma Plc, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 08, 2019: Horizon Therapeutics announces strong first-quarter 2019 financial results

Apr 11, 2019: Horizon Pharma named one of the 2019 best workplaces in health care and Biopharma by FORTUNE and Great Place to Work

Mar 18, 2019: Horizon Pharma Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy

Feb 27, 2019: Horizon Pharma reports record fourth-quarter and full-year 2018 net sales driven by orphan and rheumatology segment; announces full-year 2019 guidance

Nov 07, 2018: Horizon pharma reports third-quarter net sales growth of 20 percent driven by Orphan and Rheumatology net sales growth of 25 percent

Nov 02, 2018: The Chicago Tribune Names Horizon Pharma a 2018 top workplace

Oct 25, 2018: Horizon Pharma presents multiple retrospective analyses showing kidney transplant recipients have higher rates of gout and increased disease severity

Oct 22, 2018: Horizon Pharma announces multiple data presentations highlighting the growing burden of uncontrolled gout at the 2018 ACR/ARHP Annual Meeting

Sep 27, 2018: The north american pediatric renal trials and collaborative studies and Horizon Pharma announce new long-term cystinosis registry

Aug 08, 2018: Horizon pharma reports record quarterly net sales for orphan and rheumatology segment; increases full-year 2018 adjusted EBITDA guidance; implements new company operating structure to enhance focus on rare diseases

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Horizon Pharma Plc (HZNP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Horizon Pharma plc (Horizon Pharma) is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. The company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid 2%, Procysbi, Quinsair, Ravicti, Rayos and Vimovo. Horizon Pharma provides products and services to patients and healthcare professionals in the US. The company operates through offices in the US, Switzerland, the Netherlands and Germany. Horizon Pharma is headquartered in Dublin, Ireland.

Horizon Pharma Plc Key Recent Developments

May 08,2019: Horizon Therapeutics announces strong first-quarter 2019 financial results
Apr 11,2019: Horizon Pharma named one of the 2019 best workplaces in health care and Biopharma by FORTUNE and Great Place to Work
Mar 18,2019: Horizon Pharma Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy
Feb 27,2019: Horizon Pharma reports record fourth-quarter and full-year 2018 net sales driven by orphan and rheumatology segment; announces full-year 2019 guidance
Nov 07,2018: Horizon pharma reports third-quarter net sales growth of 20 percent driven by Orphan and Rheumatology net sales growth of 25 percent

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company